Video
Study assesses the safety and efficacy of olaparib/abiraterone combo in mCRPC
Author(s):
“This study really showed that we went now beyond 2 years for radiographic progression-free survival, which is the longest we've ever seen in the first-line setting,” says Fred Saad, MD, FRCS.
In this video, Fred Saad, MD, FRCS, discusses the background and findings of the study, “PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC),” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Saad is a professor and chief of urology, director of GU oncology, and Raymond Garneau Chair in prostate cancer at the University of Montreal Hospital Center (CHUM), as well as the director of prostate cancer research at the Montreal Cancer Institute/CRCHUM in Quebec.
